Holen Sie sich die Stockscreener-App
3.04
5.30%
-0.17
Handel nachbörslich:
3.04
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BNGO?
Forum
Prognose
Aktiensplit
Bionano Genomics Inc Aktie (BNGO) Neueste Nachrichten
Bionano Genomics Posts Q2 Margin Gain - AOL.com
Bionano Genomics 2025 Q2 Earnings Losses Narrow Sharply, 57.7% Improvement in Net Loss - AInvest
Bionano raises 2025 OGM installation target to 25 as consumables and software revenue climbs 16% - MSN
Bionano Genomics: Strategic Shifts Pay Off with Rising Margins, Stronger Recurring Revenue, and 2025 Growth Upside - AInvest
Bionano Genomics (BNGO) Q2 2025 Revenue Decline Amid Strategic Shift - GuruFocus
Bionano Genomics' Strategic Turnaround and Margin Expansion: Assessing the Sustainability of Gross Margin Gains and the Long-Term Value of the OGM Ecosystem - AInvest
Bionano Genomics Q2 2025: Key Contradictions in Strategy, Revenue Growth, and System Utilization - AInvest
Bionano Genomics, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:BNGO) - Seeking Alpha
Bionano Genomics Q2 2025 Earnings Call Transcript - MarketBeat
Bionano Genomics: A Turning Point Amid Mixed Q2 Earnings—Is the Path to Profitability Clear? - AInvest
Bionano Genomics Inc (BNGO) Q2 2025 Earnings Call Highlights: Navigating Revenue Challenges ... - Yahoo Finance
Bionano Genomics Inc (BNGO) Q2 2025 Earnings Call Highlights: Navigating Revenue Challenges with Strategic Growth Initiatives - GuruFocus
Will Bionano Genomics Inc. Benefit From Broader Market BouncePortfolio Update Summary & Free Real-Time Volume Trigger Notifications - beatles.ru
Bionano Q2: Revenue Down 15% YoY, Gross Margin Above 50% - AInvest
Earnings call transcript: Bionano Genomics Q2 2025 sees revenue drop, stock dips - Investing.com Australia
Earnings call transcript: Bionano Genomics Q2 2025 sees revenue drop, stock dips By Investing.com - Investing.com South Africa
Transcript : Bionano Genomics, Inc., Q2 2025 Earnings Call, Aug 14, 2025 - MarketScreener
Bionano Genomics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Bionano Genomics Reports Q2 Results: Revenue Down 13.4% YoY, Q3 and FY25 Outlook Reiterated. - AInvest
Bionano Reports Second Quarter 2025 Results and Highlights Recent Business Progress - MarketScreener
Major Earnings Scheduled for Release After Thursday's Close - AInvest
Bionano Genomics Q2 Earnings Preview: Consensus EPS -$2.99, Revenue $6.56M - AInvest
Bionano Genomics at Canaccord Conference: Mapping a New Path By Investing.com - Investing.com South Africa
Bionano Genomics Inc expected to post a loss of $2.41 a shareEarnings Preview - TradingView
Is Bionano Genomics Inc. forming a double bottomFree Stock Filtering Tool - newsimpact.co.kr
Bionano Genomics BNGO 2025Q2 Earnings Preview Upside Potential Driven by Strategic Partnerships and Innovations - AInvest
BioNano Genomics Eyes Growth with OGM Validation and Strategic Innovations - AInvest
Resistance Break Could Fuel Bionano Genomics Inc. RallyEarly Entry Picks Before News Breakout Reviewed - beatles.ru
BioNano Genomics: Strategic Innovations and OGM Validation Drive Buy Rating - TipRanks
Can Bionano Genomics Inc. navigate macro headwindsHidden Volume Breakout Stocks - thegnnews.com
What data driven models say about Bionano Genomics Inc.’s futureWeekly Price Target Forecast and Alerts - Newser
Bionano Genomics Inc. Stock Performance After Earnings: Historical InsightsWeekly Stock Picks with Trend Confidence - Newser
What makes Bionano Genomics Inc. stock price move sharplyShort-Term Bounce Forecast for Oversold Stocks - Newser
Bionano Announces Publication Showing Utility of Optical Genome - GuruFocus
Bionano Announces Publication Showing Utility of Optical - GlobeNewswire
Revolutionary Genome Mapping Study Achieves 100% Survival Rate in Key Pediatric Leukemia Subgroup - Stock Titan
Bionano Genomics, Inc. (NASDAQ:BNGO) Receives Average Recommendation of “Hold” from Analysts - Defense World
Is Bionano Genomics Inc. meeting your algorithmic filter criteriaSecure Trading Strategy Based on Technical Analysis - Newser
Bionano Genomics CEO to Present at Canaccord Genuity Growth Conference. - AInvest
Bionano Genomics CEO Set for Major Presentation at Canaccord's Elite Growth Conference - Stock Titan
Bionano to Present at the Canaccord Genuity 45th Annual Growth Conference - The Globe and Mail
Moving Average Trends for Bionano Genomics Inc. Stock: What They IndicateDaily Upside Movement Prediction With Data - Newser
Bionano Genomics (BNGO) Unveils Enhanced Genomic Analysis Softwa - GuruFocus
Bionano Genomics (BNGO) Unveils Enhanced Genomic Analysis Software - GuruFocus
Bionano Announces Upgrades to its Software and Compute Platforms - GuruFocus
Bionano Announces Upgrades to its Software and Compute - GlobeNewswire
Bionano's VIA 7.2 & Solve 3.8.3 enhance OGM data analysis, improve AI capabilities. - AInvest
Bionano Genomics Enhances Genomic Data Analysis with VIA 7.2 and Stratys Compute Upgrades - AInvest
Why is Bionano Genomics Inc. stock attracting strong analyst attentionDiscover market opportunities others miss - Jammu Links News
What are Bionano Genomics Inc. company’s key revenue driversExplosive wealth accumulation - Jammu Links News
Bionano Genomics 2022 Symposium - Labroots
When is Bionano Genomics Inc. stock expected to show significant growthDiscover hidden gems in the stock market - Jammu Links News
Is Bionano Genomics Inc. stock overvalued or undervaluedCapitalize on market trends before they peak - Jammu Links News
Is Bionano Genomics Inc. a good long term investmentInvest with confidence backed by data - Jammu Links News
Is it the right time to buy Bionano Genomics Inc. stockGet real-time alerts on high-potential stocks - Jammu Links News
How volatile is Bionano Genomics Inc. stock compared to the marketExceptional market positioning - Jammu Links News
Is Bionano Genomics Inc. a growth stock or a value stockRapid-fire capital growth - Jammu Links News
What drives Bionano Genomics Inc. stock priceDiscover market opportunities with real-time data - Jammu Links News
0.31%
0.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):